US Dollar vs MXN

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

VSTM Verastem Inc

11.50

-0.63 (-5.19%)

Fuera de horario

Última actualización: 17:16:21

Retrasado por 15 minutos

Form EFFECT - Notice of Effectiveness

Verastem (NASDAQ:VSTM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Verastem.

Verastem (NASDAQ:VSTM)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Verastem.

Noticias sobre Verastem Inc VSTM

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 9 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Jueves 9 de Mayo 2024 (1 semana hace) • Business Wire

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Martes 7 de Mayo 2024 (2 semanas hace) • Business Wire

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Jueves 18 de Abril 2024 (4 semanas hace) • Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jueves 4 de Abril 2024 (1 mes hace) • Business Wire

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
Lunes 18 de Marzo 2024 (2 meses hace) • Business Wire

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
Jueves 14 de Marzo 2024 (2 meses hace) • Business Wire

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
Lunes 11 de Marzo 2024 (2 meses hace) • Edgar (US Regulatory)

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
Lunes 11 de Marzo 2024 (2 meses hace) • Business Wire

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Martes 5 de Marzo 2024 (2 meses hace) • Business Wire

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
Martes 5 de Marzo 2024 (2 meses hace) • Business Wire

Form SC TO-I - Tender offer statement by Issuer
Jueves 8 de Febrero 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Verastem Inc Artículos de Noticias

Digital Media Solutions

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones